Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187264 | 0.95 | CYP2C9 (0.63) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3195407 | 0.93 | MEN1 (0.63) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3185841 | 0.93 | MEN1 (0.63) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL5353148 | 0.91 | MEN1 (0.61) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3201387 | 0.88 | TP53 (0.55) | MEN1KMT2ATP53POLBALDH1A1 | |
| SCHEMBL3198494 | 0.86 | KMT2A (0.59) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3193731 | 0.85 | MEN1 (0.56) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3197498 | 0.84 | KMT2A (0.61) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3185487 | 0.83 | KMT2A (0.59) | MEN1KMT2ACYP1A2CYP2C9TP53 | |
| SCHEMBL3189962 | 0.82 | MEN1 (0.68) | MEN1KMT2ACYP1A2CYP2C9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007115232-A2 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | MEN1 4362/4885KMT2A 3838/4885CYP1A2 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.